US 10626393
Delivering CRISPR therapeutics with lipid nanoparticles
granted A61KA61K48/0025A61K9/127
Quick answer
US patent 10626393 (Delivering CRISPR therapeutics with lipid nanoparticles) held by ARBUTUS BIOPHARMA CORPORATION expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ARBUTUS BIOPHARMA CORPORATION
- Grant date
- Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K48/0025, A61K9/127, A61K9/5123, A61K9/5146